For a 200‑lb (≈91 kg) patient, what starting dose of Depakote ER (valproic acid extended‑release) should be used?

Starting Dose of Depakote ER for a 200-lb Patient

For a 200-lb (91 kg) patient, start Depakote ER at 1,000 mg once daily for seizures or 2,275 mg once daily for acute mania.

Indication-Specific Dosing

The starting dose depends critically on the indication:

For Seizures (Complex Partial or Absence)

• Start at 10–15 mg/kg/day 11
• For a 91 kg patient: 910–1,365 mg/day
• Practical starting dose: 1,000 mg once daily (using available 500 mg tablets)
• Increase by 5–10 mg/kg/week (455–910 mg/week) until optimal response
• Maximum dose: 60 mg/kg/day (5,460 mg/day) 11

For Acute Mania

• Start at 25 mg/kg/day 11
• For a 91 kg patient: 2,275 mg once daily
• Increase rapidly to achieve therapeutic response or plasma levels of 85–125 mcg/mL
• Maximum dose: 60 mg/kg/day (5,460 mg/day) 11

Research supports that oral loading at 20–30 mg/kg/day in acute mania achieves therapeutic levels (≥50 mcg/mL) within 2–3 days with minimal side effects 23. One study using 30 mg/kg/day (approximately 2,730 mg for this patient) achieved average levels of 93.2 mcg/mL by day 3, with therapeutic levels in most patients 2.

For Migraine Prophylaxis

• Start at 500 mg once daily for 1 week
• Then increase to 1,000 mg once daily 1
• Weight-based dosing is not specified for this indication

Critical Dosing Considerations

Swallow tablets whole—do not crush or chew 11. Depakote ER is designed for once-daily administration with extended-release kinetics that would be disrupted by crushing.

Obesity Adjustment

For obese patients (BMI ≥30), consider using adjusted body weight (AdjBW) rather than total body weight for dosing calculations 4. This approach minimizes toxicity risk while maintaining efficacy. The formula: AdjBW = IBW + 0.4 × (TBW - IBW).

Monitoring Requirements

• Baseline liver function tests before starting 1
• Check valproate level on day 3 if using loading dose for mania 2
• Target therapeutic range: 50–100 mcg/mL for seizures; 85–125 mcg/mL for mania 11
• Monitor platelets and coagulation (thrombocytopenia risk increases significantly at trough levels >110 mcg/mL in females, >135 mcg/mL in males) 1

Common Pitfalls to Avoid

1. Don't underdose in mania: The FDA-approved starting dose for mania (25 mg/kg/day) is substantially higher than for seizures (10–15 mg/kg/day). Using seizure dosing for mania delays therapeutic response.

2. Don't use total body weight in obese patients without consideration: This may lead to supratherapeutic levels and increased toxicity risk 4.

3. Don't forget contraindications: Depakote ER is absolutely contraindicated in hepatic disease, urea cycle disorders, and known hypersensitivity 11.

4. Teratogenicity warning: For women of childbearing potential, the risk of neural tube defects and other teratogenic effects must be thoroughly discussed before initiating therapy 11.

5. Watch for hyperammonemia: Particularly with concomitant topiramate use, which can precipitate hyperammonemic encephalopathy even with normal valproate levels 1.

Titration Strategy

After the initial dose:

• Seizures: Increase by 5–10 mg/kg/week based on clinical response and plasma levels 1
• Mania: Increase as rapidly as possible to achieve therapeutic response 11
• If response is inadequate at doses <60 mg/kg/day, check plasma levels before further escalation 1

The probability of thrombocytopenia increases significantly above 60 mg/kg/day, so weigh the benefit of higher doses against increased adverse event risk 1.